top of page

Back to Team

Leading Team


Jeff George

Earlier his career, Jeff headed Emerging Markets (Middle East, Africa, Southeast Asia, and CIS) at Novartis Pharmaceuticals, leading a team of over 3,000 people across 65 markets and serving on its Executive Committee. He previously served as Vice President and Head of Western & Eastern Europe for Novartis Vaccines. Before joining Novartis, Jeff was a Senior Director of Strategic Planning & Business Development at Gap Inc., and an Engagement Manager with McKinsey & Co., both in San Francisco.


Jeff holds an MBA from Harvard Business School and a master’s degree from Johns Hopkins University’s School of Advanced International Studies (SAIS), where he studied international economics and emerging markets political economy and was a John W. Watzek Fellow. He received his B.A. in international relations, magna cum laude and Phi Beta Kappa, from Carleton College.


Jeff has been a member of the Young Presidents’ Organization (YPO) since 2013, where he serves on the Dallas Board, and previously served on the Board of Directors for AdvaMed, the medical device industry association. He was twice named to Fortune’s “40 under 40” list of up-and-coming leaders globally and has lived in seven countries on four continents.  Jeff is married and lives with his wife and two daughters in Dallas and enjoys running, skiing, live music, yoga, meditation, travel, and foreign affairs.

  • LinkedIn

Jeff is the Managing Partner of Maytal Capital, a healthcare-focused private equity investment and advisory firm he founded in 2017, and an Operating Partner at Revival Healthcare Capital, a medical device-focused private equity firm.  He previously served as the global CEO for Sandoz and Alcon at Novartis Group (NYSE: NVS), where he served on the executive committee between 2008 and 2016. 


Jeff currently serves on the board of directors at Amneal Pharmaceuticals (NYSE: AMRX), a leading specialty and generic pharma company with ~$2 billion in sales; Wishbone Medical, a global leader in pediatric orthopedic medical devices; and Dorian Therapeutics, a pre-clinical biotech firm spun out of Stanford Medical School which is a pioneer in the cellular anti-senescence field.  He also serves the boards of several leading non-profit organizations including Education Opens Doors, where he is Chairman, the North Texas Food Bank, one of Texas’s largest non-profits, and YPO of Dallas.  Jeff previously served on the board of Roam Analytics, a Silicon Valley-based artificial intelligence healthcare software firm which was sold in 2020 to Parexel, a leading biopharma CRO.


Between 2008 and 2016, Jeff served on the Executive Committee of Novartis Group, a Fortune 100 pharmaceutical company based in Switzerland, first as CEO and Division Head of Germany-based Sandoz, Novartis’s $10 billion revenue generic pharmaceutical and biosimilar subsidiary, which more than doubled in value during his tenure. He was then named CEO and Division Head of Texas- based Alcon, Novartis’s ~$10 billion revenue ophthalmology subsidiary, which was spun out from Novartis in 2019 as an independently-listed company (NYSE: ALC). At both Sandoz and Alcon, Jeff was responsible for leading over 25,000 associates globally across more than 160 countries and had primary line leadership and management responsibility for all functions, regions, and franchises. More recently, he served as CEO and Board Director of Performance Health, a leader in consumer healthcare and the largest global manufacturer and distributor to the physical therapy, rehab, and sports medicine markets.


bottom of page